NO924103L - Anvendelse av antistoffholdige preparater for immunundertrykkelse - Google Patents

Anvendelse av antistoffholdige preparater for immunundertrykkelse

Info

Publication number
NO924103L
NO924103L NO92924103A NO924103A NO924103L NO 924103 L NO924103 L NO 924103L NO 92924103 A NO92924103 A NO 92924103A NO 924103 A NO924103 A NO 924103A NO 924103 L NO924103 L NO 924103L
Authority
NO
Norway
Prior art keywords
antibody
substances
repression
immune
immune repression
Prior art date
Application number
NO92924103A
Other languages
English (en)
Other versions
NO311965B1 (no
NO924103D0 (no
Inventor
Margot Zoeller
Peter Herrlich
Helmut Ponta
Original Assignee
Kernforschungsz Karlsruhe
Deutsches Krebsforsch
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kernforschungsz Karlsruhe, Deutsches Krebsforsch, Boehringer Ingelheim Int filed Critical Kernforschungsz Karlsruhe
Publication of NO924103D0 publication Critical patent/NO924103D0/no
Publication of NO924103L publication Critical patent/NO924103L/no
Publication of NO311965B1 publication Critical patent/NO311965B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO19924103A 1991-10-23 1992-10-22 Anvendelse av antistoffer rettet mot variant -CD44- (vCD44)- overflateprotein for fremstilling av et farmasöytisk preparat NO311965B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4134982A DE4134982A1 (de) 1991-10-23 1991-10-23 Verwendung von antikoerper enthaltenden praeparationen zur immunsuppression

Publications (3)

Publication Number Publication Date
NO924103D0 NO924103D0 (no) 1992-10-22
NO924103L true NO924103L (no) 1993-04-26
NO311965B1 NO311965B1 (no) 2002-02-25

Family

ID=6443260

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19924103A NO311965B1 (no) 1991-10-23 1992-10-22 Anvendelse av antistoffer rettet mot variant -CD44- (vCD44)- overflateprotein for fremstilling av et farmasöytisk preparat

Country Status (17)

Country Link
US (1) US5951982A (no)
EP (1) EP0538754B1 (no)
JP (1) JPH05310596A (no)
KR (1) KR100252620B1 (no)
AT (1) ATE162079T1 (no)
AU (1) AU659687B2 (no)
CA (1) CA2081150C (no)
DE (2) DE4134982A1 (no)
DK (1) DK0538754T3 (no)
ES (1) ES2111031T3 (no)
GR (1) GR3026526T3 (no)
HU (1) HU216020B (no)
IL (1) IL103510A0 (no)
NO (1) NO311965B1 (no)
NZ (1) NZ244851A (no)
TW (1) TW273514B (no)
ZA (1) ZA928162B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589458A (en) * 1992-11-13 1996-12-31 Thomas Jefferson University Compounds that inhibit T cell proliferation and methods for using the same
ATE159953T1 (de) * 1993-06-18 1997-11-15 Biotie Therapies Oy Zusammensetzungen und diagnostische verfahren unter verwendung von monoklonalen antikoerpern gegen cd44v6
DE4326573A1 (de) * 1993-08-07 1995-02-23 Boehringer Ingelheim Int Durch Exon v5 des CD44-Gens kodierte Polypeptide als Targets für Immuntherapie und Immunszintigraphie von Tumoren
DE4431297A1 (de) * 1994-09-02 1996-03-07 Boehringer Ingelheim Int Monoklonaler Antikörper gegen CD44v6
DE19540515C1 (de) * 1995-10-31 1997-02-06 Boehringer Ingelheim Int Tumortherapie durch adoptiven Transfer CD44v-spezifischer zytotoxischer T-Lymphozyten
AU1672097A (en) * 1996-02-15 1997-09-02 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody that recognizes antigens present on the surface of endothelial cell of tumor vessel
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
DE19652815C2 (de) * 1996-12-18 1999-11-11 Karlsruhe Forschzent Mittel zur Identifizierung und Therapie metastasierender Tumore
DE19653607A1 (de) 1996-12-20 1998-06-25 Boehringer Ingelheim Int Verfahren zur Diagnose und Therapie von Hodgkin-Lymphomen
DE19708713C2 (de) * 1997-03-04 2002-11-28 Boehringer Ingelheim Int Verwendung von anti-CD44 Antikörpern enthaltenden Präparationen zur Behandlung bestimmter Tumore und zur Unterdrückung von Immunreaktionen
IL121656A0 (en) * 1997-08-29 1998-02-08 Yissum Res Dev Co Diagnosis prevention and treatment of diabetes
US7534605B2 (en) 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US20040110933A1 (en) * 2002-09-13 2004-06-10 Dyax Corporation CD44-binding ligands
US9701754B1 (en) 2002-10-23 2017-07-11 City Of Hope Covalent disulfide-linked diabodies and uses thereof
US20070280930A1 (en) * 2004-03-17 2007-12-06 Kasper Mathias Antoon Rouschop Cd44-Targeting for Reducing/Preventing Ischemia-Reperfusion-Injury
EP1924606A4 (en) 2005-08-25 2010-01-13 Repair Technologies Inc DEVICES, COMPOSITIONS AND METHODS FOR PROTECTING AND REPAIRING CELLS AND TISSUE
CA2646329C (en) 2006-03-20 2018-07-03 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
WO2009032949A2 (en) 2007-09-04 2009-03-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
WO2010058396A1 (en) 2008-11-19 2010-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. A cd44vra antibody and diagnostic and therapeutic methods using same
ES2712732T3 (es) 2009-02-17 2019-05-14 Cornell Res Foundation Inc Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
AU2010325969B2 (en) 2009-12-02 2016-10-20 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen
ES2639855T3 (es) 2013-12-23 2017-10-30 Exchange Imaging Technologies Gmbh Nanopartícula conjugada a péptidos de unión a CD44
EP3169343B1 (en) 2014-07-15 2020-03-25 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Isolated polypeptides of cd44 and uses thereof
US11254744B2 (en) 2015-08-07 2022-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
US11313243B2 (en) 2018-07-12 2022-04-26 Rolls-Royce North American Technologies, Inc. Non-continuous abradable coatings

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0303463B1 (en) * 1987-08-11 1994-11-30 The Board Of Trustees Of The Leland Stanford Junior University Method to control leukocyte extravasation
DE4014510A1 (de) * 1990-05-07 1991-11-14 Kernforschungsz Karlsruhe Variante cd44-oberflaechenproteine, diese kodierende c-dna-sequenzen, antikoerper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie
CA2059824A1 (en) * 1991-02-26 1992-08-27 Thomas M. Aune Hybridomas and monoclonal antibodies that inhibit anti-cd3-stimulated t cell proliferation
ATE159953T1 (de) * 1993-06-18 1997-11-15 Biotie Therapies Oy Zusammensetzungen und diagnostische verfahren unter verwendung von monoklonalen antikoerpern gegen cd44v6

Also Published As

Publication number Publication date
NO311965B1 (no) 2002-02-25
ATE162079T1 (de) 1998-01-15
JPH05310596A (ja) 1993-11-22
CA2081150C (en) 2001-04-10
AU2724492A (en) 1993-04-29
EP0538754A3 (en) 1994-05-25
DE4134982A1 (de) 1993-04-29
GR3026526T3 (en) 1998-07-31
HUT63063A (en) 1993-07-28
IL103510A0 (en) 1993-03-15
TW273514B (no) 1996-04-01
KR100252620B1 (ko) 2000-09-01
ES2111031T3 (es) 1998-03-01
EP0538754B1 (de) 1998-01-14
EP0538754A2 (de) 1993-04-28
NO924103D0 (no) 1992-10-22
DE59209129D1 (de) 1998-02-19
AU659687B2 (en) 1995-05-25
CA2081150A1 (en) 1993-04-24
ZA928162B (en) 1993-05-05
DK0538754T3 (da) 1998-03-30
NZ244851A (en) 1997-07-27
HU216020B (hu) 1999-04-28
KR930007460A (ko) 1993-05-20
US5951982A (en) 1999-09-14

Similar Documents

Publication Publication Date Title
NO924103D0 (no) Anvendelse av antistoffholdig preparater for immunundertrykkelse
DK0791571T3 (da) Benzoylderivater
FI924982A7 (fi) Pakastekuivattu preparaatti joka sisältää monokloonista vasta-ainetta
FI882173A7 (fi) Synteettinen peptidiantigeeni HIV-2-tartunnan toteamiseksi.
FI950277L (fi) Ksenogeenisten vasta-aineiden tuotanto
FI906202A0 (fi) Obemannat disksystem.
NO864971L (no) Fremgangsmaate for fremstilling av monoklonale antistoffer som er kryssbeskyttende overfor p. aeruginosaserotyper.
JPS57116100A (en) Novel d-homosteroid
NO893088D0 (no) Fremgangsmaate for fremstilling av terapeutisk virksomme somatostatinlignende cykliske peptidforbindelser.
FI945865L (fi) Glykoprofeiini P:lle kohdistettuja monoklonaalisia vasta-aineita
DE3577722D1 (de) Derivat des adult-t-zell-leukemiavirus-antigenpeptids.
DK0638068T3 (da) Fremgangsmåde til fremstilling af (S)-3-amino-1-substitueret-pyrrolidiner
FI892222A0 (fi) Peptidalkoholer med antikoagulantverkan.
FI883092A7 (fi) Immuunivastetta rajoittavat peptidit
FI882079A0 (fi) Foerfarande foer framstaellning av en genetiskt kodbar polypeptid.
NO910594L (no) Anordning til induktiv tenning av drivladninger.
NO920636D0 (no) Fremgangsmaate for fremstilling av 9-amino-1,2,3,4-tetra-hydroakridin
ITRM910385A0 (it) Vaccini utilizzanti eritrociti come veicoli di antigeni.
ATE136884T1 (de) Neue 2-mercaptomethylen-tetrahydronaphthalin- und -indan-2-carboxamide als enkephalinaseinhibitoren
ITMI910660A0 (it) Anticorpi monoclonali come antidoti
FI913414A0 (fi) Foerfarande foer framstaellning av 2-hydroxi-3-halogen-5-nitropyridiner.
IT8321802A0 (it) Varieta' di alstroemeria di colore rosa impero.
DK0511516T3 (da) Schizosaccharomyces-specifikke polypeptider
SE9201176D0 (sv) Ihopfaellbar laada tillverkad av plywood
FI870860A0 (fi) Anordning foer hindrande av bilstoeld.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees